mo:re funding news – Hamburg-based mo:re Secures €2.3Million in Seed Funding

The funding round was led by High-Tech Gründerfonds (HTGF), with additional investments from Innovationsstarter Fonds Hamburg (IFH), Gilson Inc., NEDGEX, Nidobirds Ventures, and private investors R&R Medical and Martin Blüggel. The company's valuation was not disclosed.

The money will help mo:re launch its first product, develop more organ models, and promote its automated 3D cell culture platform. The goal is to improve drug development by offering reliable, high-throughput organoid models and reducing the need for animal testing.

mo:re’s new platform was revealed at SLAS 2025 in San Diego, the top event for laboratory automation. It simplifies the planning, growth and analysis of 3D cell cultures.

Read also - EcoDataCenter funding news – EcoDataCenter Secures €450 Million in Funding

Unlike other solutions that only focus on one part of the process, mo:re’s device handles all stages of the workflow ensuring high consistency and scalability. The easy-to-use system removes the need for expert knowledge in organ biology, making advanced cell culture methods available to more researchers.

Lukas Gaats, CEO of mo:re, emphasised the impact of this funding on the company’s growth: “With this funding, we want to establish our presence in the market and continue building our team. Now it is time to focus our resources on developing further scientific applications to unlock the potential our platform has to offer together with our customers as well as our internal R&D lab.”

Dr Christian Kannemeier, Senior Investment Manager at HTGF highlighted the company’s potential: “The team of mo:re is poised to execute on its vision to provide easy access to a standardised way of performing 3D cell culture and obtain reproducible results for researchers worldwide.”

Investors see immense value in mo:re’s technology, recognising its potential to reshape laboratory automation. Stefanie Höhn Senior Investment Manager at IFH stated: “Our investment in mo:re reflects our confidence in their visionary product to tackle cell culture challenges. Their platform can redefine the landscape of non-animal methods in the life science industry.”

Dirk Freystadt, SVP Corporate Development at Gilson Inc., also underscored the importance of verifiable data in drug discovery: “Verifiable data in drug discovery and development are crucial for accelerating creation of new and effective pharmaceuticals. mo:re’s innovative technological approach provides an important step toward standardising organoid growth, significantly enhancing their quality. This will not only improve the speed and reliability of drug discovery but also deliver more consistent results for research, ultimately reducing the reliance on animal testing.”

About mo:re

mo:re was started in 2023 by Lukas Gaats and David Hackenberger, who met during their MBA studies at TU Hamburg in 2018. Unlike other companies in lab automation and bioprinting, mo:re offers a complete solution for automating tissue culture. While others focus on just one part of the process mo:re provides a smooth all-in-one workflow that removes delays and inconsistencies.